With patients as our guiding stars, Astria Therapeutics’ dedicated and passionate team is devoted to bringing life-changing therapies to patients and families impacted by allergic and immunologic diseases.

At Astria, we are focused on developing differentiated therapeutics for allergic and immunologic diseases. Our pipeline represents our vision to improve patients’ quality of life by creating first-choice treatments based on established mechanisms designed to …

The prefix “nav-” represents Astria’s commitment to navigating the development of navenibart with patients as our guiding stars. The infix “-eni-” represents “enzyme inhibitor” and the suffix “-bart” represents “monoclonal antibody.”

At Astria, our guiding star is to benefit our patients, address their unmet needs, and improve their quality of life. Our compassion for patients also brings with it a natural sense of urgency, agility, and operational efficiency in all that we do.

Chris Morabito has served as Chief Medical Officer at Astria since July 2022. Previously, he was Chief Medical Officer at Fulcrum Therapeutics from May 2021 to July 2022. From July 2020 to May 2021, Dr. Morabito served as Chief Medical Officer at Cardurion Pharmaceuticals.

Astria’s mission of bringing hope with life-changing therapies is propelled by the voice of the patient. We listen to the communities of those impacted by allergic and immunologic diseases, learn from, and are guided by their experiences, and work to create therapies that treat the disease and improve patient quality of life.

If you are interested in exploring employment opportunities at Astria, please click on the button below to view our current openings. View Current Openings Astria Therapeutics is an Equal Opportunity Employer committed to diversity, equity, & inclusion.

Address: 22 Boston Wharf Road 10th Floor Boston, MA 02210. P: 617-349-1971 F: 617-273-2637

ABOUT THE ALPHA-STAR PHASE 1b/2 CLINICAL TRIAL. ALPHA-STAR is a clinical trial for people living with HAE types I and II that is evaluating STAR-0215 as a potential long-acting treatment for prevention of HAE attacks. STAR-0215 is an investigational drug, which has not yet been authorized by government authorities for use other than in clinical trials.

Using half-life extension technology with the aim of durable efficacy with less frequent dosing every 2-3 months, STAR-0310 is designed with the potential to be a first-choice treatment that reduces disease and treatment burden to help normalize the lives of people with atopic dermatitis.